(Q22251070)

Aids-related malignancies

volume

2

0 references

page(s)

406-415

0 references

406-15; quiz 423

0 references

issue

8

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038/NCPONC0253

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/NCPONC0253

Spectrum of AIDS-associated malignant disorders

20 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Cancer incidence in New York State acquired immunodeficiency syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains hypoxia response elements: relevance to lytic induction by hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

21 January 2018

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Epidemiology of AIDS-related malignancies an international perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

HIV-associated lymphoma: promising new results, but with toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

A pilot study of cidofovir in patients with kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Association of Cancer With AIDS-Related Immunosuppression in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Monoclonal Origin of Multicentric Kaposi's Sarcoma Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

Retrovirus and malignant lymphoma in homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Public health. Whatever happened to the U.S. AIDS epidemic?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS Malignancy Consortium and IM862 Study Team

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Activity of thalidomide in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Imatinib-induced regression of AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Additional experience with empiric radiotherapy for presumed human immunodeficiency virus-associated primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

The tumor microenvironment controls primary effusion lymphoma growth in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0253

7 January 2021

Identifiers

DOI

10.1038/NCPONC0253

1 reference

Consolidated OpenCitations Corpus – April 2017

3005937

3005937

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference